1 week Ago By Defense World Staff
Norges Bank acquired a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 161,000 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.
Norges Bank owned about 0.15% of Revance Therapeutics at the end of the most recent quarter. Several other large investors have also modified their holdings of RVNC.
Mint Tower Capital Management B.V. boosted its holdings in Revance Therapeutics by 212.
4% during the fourth quarter. Mint Tower Capital Management B.V.
now owns 187,443 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 127,443 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Revance Therapeutics during the 4th quarter worth about $74,000. Magnetar Financial LLC lifted its position in shares of Revance Therapeutics by 2.
2% during the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after purchasing an additional 56,174 shares during the last quarter. Candriam S.
C.A. bought a new stake in Revance Therapeutics during the 4th quarter valued at approximately $909,000.
Finally, Charles Schwab Investment Management Inc. increased its position in Revance Therapeutics by 0.8% in the 4th quarter.
Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock worth $2,424,000 after buying an additional 6,462 shares during the period. 97.
70% of the stock is owned by institutional investors. Revance Therapeutics Stock PerformanceShares of RVNC stock opened at $3.65 on Friday.
The firm has a fifty day moving average of $3.65 and a 200-day moving average of $3.96.
The stock has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.
90. Revance Therapeutics, Inc. has a 52-week low of $2.
30 and a 52-week high of $6.65. Analyst Ratings ChangesSeveral equities research analysts have recently weighed in on the company.
Barclays reduced their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd.
StockNews.com began coverage on shares of Revance Therapeutics in a report on Friday. They issued a “hold” rating for the company.
Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.
com, Revance Therapeutics has an average rating of “Hold” and a consensus target price of $8.39.Check Out Our Latest Stock Analysis on RVNCAbout Revance Therapeutics (Free Report)Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.Recommended StoriesFive stocks we like better than Revance TherapeuticsTSX Venture Exchange (Formerly Canadian Venture Exchange)Robinhood Strategies Could Be a Game-Changer for Young InvestorsHow to Invest in the Best Canadian Stocks Are These 3 Retail Stocks Oversold or Really in Trouble?Canada Bond Market Holiday: How to Invest and Trade IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
